The patient went on to pursue a successful career as a staff member in China. After one year of maintenance immunotherapy, he reported no discomfort and this has clearly improved the quality of life. The regimen was maintained as the patient remained symptom-free and the results of the review were satisfactory. According to NSCLC guidelines, bevacizumab in combination with an immune checkpoint inhibitor significantly prolongs progression-free survival and/or overall survival in this disease, and the patient is currently in good health[9]. As things stand, his risk of lung adenocarcinoma recurrence is low, which is reassuring, especially since his career will require a long-term deployment with limited medical resources. However, if any symptoms of lung adenocarcinoma develop during deployment, then further medical intervention will be necessary.